Life after Merck: What Idenix's Renaud did next
This article was originally published in Scrip
In June, Merck & Co announced it was bolstering its position in the highly competitive hepatitis C arena with the acquisition of Idenix Pharmaceuticals for $3.85bn (scripintelligence.com, 9 June 2014). The transaction closed in August.
You may also be interested in...
Dyne Launches With $50m For Antibody Conjugates That Deliver Oligonucleotides To Muscles
The start-up incubated by Atlas Venture is focused on the delivery of nucleic acids and other molecules to skeletal, cardiac and smooth muscles. The Series A round will allow Dyne to take its lead program for myotonic dystrophy type 1 (DM1) into the clinic.
Early Stage Candidates Carving Out New Routes In Cystic Fibrosis
Scrip spoke to two companies from a fresh wave of innovators that are approaching drug development for cystic fibrosis from a new angle.
Vertex Set To Dominate Cystic Fibrosis Market For The Next Decade
Vertex is set to reap huge benefits from its triple combination program for cystic fibrosis over the next 10 years, potentially becoming the biggest selling drug in this disease, according to a new report from Datamonitor Healthcare.